Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141633 | 0.78 | LMNA (0.39) | LMNACES2 | |
| SCHEMBL31545085 | 0.76 | LMNA (0.70) | LMNACES2MEN1CYP3A4ALOX15 | |
| SCHEMBL4440899 | 0.74 | LMNA (0.42) | LMNACES2MEN1CYP3A4ALOX15 | |
| SCHEMBL13782375 | 0.74 | LMNA (0.42) | LMNACES2MEN1CYP3A4ALOX15 | |
| SCHEMBL4402841 | 0.74 | LMNA (0.42) | LMNACES2MEN1CYP3A4ALOX15 | |
| SCHEMBL9706627 | 0.74 | LMNA (0.47) | LMNACES2ALDH1A1MEN1CYP3A4 | |
| SCHEMBL5698477 | 0.74 | LMNA (0.42) | LMNACES2MEN1CYP3A4ALOX15 | |
| SCHEMBL13726989 | 0.74 | LMNA (0.42) | LMNACES2ALDH1A1TP53HTT | |
| SCHEMBL13985486 | 0.72 | LMNA (0.41) | LMNACES2ALDH1A1MEN1CYP3A4 | |
| SCHEMBL7792048 | 0.71 | LMNA (0.40) | LMNACES2MEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012150292-A1 | STEREOSELECTIVE SYNTHESIS OF CIS-4-METHYLSPHINGOSINE AND DERIVATIVES THEREOF | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012150292-A1 | STEREOSELECTIVE SYNTHESIS OF CIS-4-METHYLSPHINGOSINE AND DERIVATIVES THEREOF | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2012-11-08 | — | — | WO | disclosed |
| US-6867323-B2 | Cross-coupling reaction of organosilicon nucleophiles | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN | 2002-12-05 | — | — | US | disclosed |
| WO-2001094355-A1 | CROSS-COUPLING REACTION OF ORGANOSILICON NUCLEOPHILES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183516-A1 | Cross-coupling reaction of organosilicon nucleophiles | TST, HPD, PCNA | LMNA 4232/4885CES2 3395/4885ALDH1A1 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.